February 22, 2021August 24, 2022
Enhertu Approved in UK for Inoperable, Advanced Breast Cancer
News
Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic ... Read more
February 18, 2021February 18, 2021
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC
News
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in ... Read more
February 15, 2021February 15, 2021
Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer
News
Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously ... Read more
February 11, 2021February 11, 2021
Trial Testing AL101 in TNBC Doses First Patient
News
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy ... Read more
February 8, 2021February 8, 2021
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
News
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative ... Read more
February 4, 2021February 4, 2021
Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors
News
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide ... Read more
February 1, 2021February 1, 2021
US Study Enrolling Women to Help Determine Best Screening Practices
News
A national study is seeking women in the U.S. to help determine the safest and best way to screen for ... Read more
January 28, 2021January 28, 2021
Nonprofit Highlights Importance of Global Teamwork for World Cancer Day
News
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation ... Read more
January 25, 2021January 25, 2021
Enhertu Approved in EU for Inoperable, Advanced Breast Cancer
News
The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer ... Read more
January 21, 2021January 21, 2021
Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA
News
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and ... Read more
January 18, 2021January 18, 2021
Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors
News
Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The ... Read more
January 14, 2021January 14, 2021
Genetic Test for Advanced Breast Cancer Launched in EU
News
Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic ... Read more

November 8, 2019November 8, 2019

Most Breast Cancers Found by Hand, MammaCare Researchers Say

News

Decades after establishing the recognized standard for performing and teaching clinical and personal breast exams, the MammaCare Foundation wants women and others to be aware that most breast cancers are ... Read more

November 6, 2019

First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer

News

A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company ... Read more

November 4, 2019

Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests

News

Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who have ... Read more

November 1, 2019December 30, 2019

Pathologist Creates Program Allowing Patients to Face Their Cancer Head-on

News

Massachusetts pathologist Lija Joseph, MD, has created an innovative program that allows patients, including those with breast cancer, to actually see the cells that make up their malignancies. In doing ... Read more

October 30, 2019

Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows

News

People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination ... Read more

October 28, 2019October 28, 2019

FDA Supports Use of Anti-diarrheal Medications with Nerlynx

News

The U.S. label of Nerlynx (neratinib), a treatment for early stage HER2-positive breast cancer, now includes information on the use of two anti-diarrheal medications to prevent severe side effects of the therapy. ... Read more

October 25, 2019November 11, 2019

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

News

Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings ... Read more

October 23, 2019October 24, 2019

Daiichi Sankyo Files New Drug Application for DS-8201 in Japan

News

Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. ... Read more

October 21, 2019December 30, 2019

Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency has ... Read more

October 18, 2019October 28, 2019

Keytruda-chemo Combo Best for Clearing Tumors in Early TNBC, Latest Trial Data Show

News

Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or ... Read more

October 16, 2019

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. ... Read more

October 14, 2019October 14, 2019

Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows

News

Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy ... Read more

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Trial Testing AL101 in TNBC Doses First Patient

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

US Study Enrolling Women to Help Determine Best Screening Practices

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Genetic Test for Advanced Breast Cancer Launched in EU